Artificial intelligence models have successfully designed functional bacteriophages in a laboratory setting, marking a significant milestone in AI-driven biological research. The systems, called Evo1 and Evo2, were developed at Stanford University and represent a breakthrough in using machine learning to create novel biological agents.
The bacteriophages created by these AI systems show promise in treating bacterial infections affecting the intestines, urinary tract, and respiratory system. Unlike the viral threats typically associated with headlines, these engineered viruses target only bacteria and pose no risk to human health.
Stanford researchers prioritized safety by deliberately excluding certain viral sequences from the training data. Specifically, they removed genetic information from viruses capable of infecting complex organisms, effectively building safeguards into the AI models themselves. This approach demonstrates that AI can generate novel biological solutions while maintaining careful control over potential risks.
